The CLERAD journey began in 2000, driven by founder Philippe Brette (PhD Physics).
Over more than 25 years, the company has established itself as a leader in ionizing radiation detection, specializing in medical applications for the identification and treatment of radiolabelled tissues.
Today, CLERAD operates across the entire end-to-end care space, from diagnostic support to treatment, in nuclear medicine, radiology, surgery, radiotherapy and chemotherapy.
We design, develop and distribute medical devices with a clear ambition: to enable more precise, safer, less invasive procedures in support of optimized patient care and therapeutic deescalation.
Driven by the expertise of our teams, we are continuously expanding our portfolio of purpose-dedicated oncology technologies, offering a comprehensive range of devices for diagnosis, surgical guidance and treatment, tailored to each patient.
1998
Participation of our R&D team in a multicentre protocol on the sentinel lymph node technique, aimed at improving radiolabelled tissue detection.
2000
Philippe Brette (PhD Physics), founded CLERAD with a focus on high-energy physics applications.
2001
Launch of CLERAD’s first product, the Gamma-Sup, followed by the development of gamma cameras adapted to sentinel lymph node procedures.
2010
CE marking (without a notified body, under Annex II, from design through to commercialization and after-sales) for our probes and cameras.
2012
Evolution of Gamma Sup for Gamma Sup II.
2014
Creation of a subsidiary in United-States
2017
CLERAD is starting the process for compliance with the new European regulation (2017/745EU).
2021
CLERAD Obtains CE marking for the system
Papillon+ and investment in Ariane Medical
Systems Ltd.
2025
Continued external growth with Ariane Medical Systems Ltd.
CLERAD is a manufacturer that holds firm end-to-end command over its entire product value chain.
Design and development are carried out by expert physicists, electronics engineers and software engineers.
We run industrial production of Class IIa and IIb medical devices in compliance with all applicable standards.
To guarantee the availability of critical equipment, aftersales service is fully integrated at our headquarters, to guarantee reactive response within 48 hours.
We cover the entire care pathway, from diagnosis to treatment:
CLERAD delivers coherent end-to-end solutions for comprehensive disease management, such as in , from initial detection to final excision.
Our priorities revolve around customer satisfaction and patient safety.
CLERAD is ISO 13485:2016-certified by GMED for all of its activities.
Our products hold the necessary markings and authorizations for worldwide use:
CE marking
(Directive 93/42/EEC)
for our probes and cameras
FDA authorizations
for the United States
Health Canada
approvals
The content of this website is exclusively intended for healthcare professionals.
